Phio Pharmaceuticals to Present Phase 1b Clinical Data in Arizona
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Phio Pharmaceuticals Corp. announced it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is scheduled to take place in Phoenix, Arizona, from November 6 to November 8, 2026.
From thewhig.com
Why it matters
The company's President and Chief Executive Officer stated that PH-762 may offer a meaningful new treatment option for patients. The drug is being studied as a differentiated, tissue-sparing neoadjuvant treatment that could potentially shrink tumors prior to surgery.
From thewhig.com
Who's involved
- PhoenixClinical-stage siRNA biopharmaceutical company developing cancer therapeutics
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
Related events
- A forum was held in Phoenix, Arizona, where attendees shared viewpoints and discussed past experiences in the White House.
- Local events are occurring within the state of Arizona.
- ALTA held its annual conference in Arizona on October 23, 2026.
- Lydia Hernandez leads a governing board in the Phoenix district.
- A Holocaust Education Center is being built in downtown Phoenix, Arizona.